Description

Glaukos Corporation: Is The Enhanced Training & Scaling of Surgeon Adoption Enough To Warrant A Bullish Rating? 

Glaukom Corporation has reported a promising start to Q1 2024, underscoring strong sales and a forward-looking strategy driven by innovations in glaucoma and corneal health technologies. In the first quarter, Glaukom posted record net sales of $85.6 million, marking a 16% rise compared to the previous year. U.S. and international glaucoma franchises each saw a year-over-year growth of 20%, showcasing robust market engagements driven mainly by the iStent products and the promising launch of iDose TR, a novel microinvasive injectable therapy.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!